Adverse event profiles of dipeptidyl peptidase-4 inhibitors: Data mining of the public version of the FDA adverse event reporting system
This month, the Central Drugs Standard Control Organization (CDSCO) has approved Ranibizumab for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Visual Impairment Due to Diabetic Macular Oedema (DME) As diabetes and age-related eye diseases continue to rise, innovations that help preserve vision are becoming more critical than ever
Though theres no strong evidence that Ozempic is explicitly unsafe, theres also no research proving its safe for breastfeeding mothers
Notably, TD leads to disturbed expression of junction protein subtypes in Ctenopharyngodon idella (181)
Discreet Packaging Plain, unmarked packaging with no product labels or company branding visible
That study is due to generate results shortly, and Lilly is required to perform an analysis of major adverse cardiovascular events (MACE), i.e., cardiovascular death, non-fatal myocardial infarction, hospitalisation for unstable angina, and non-fatal stroke, as well as the potential for drug-induced liver injury (DILI)